Korea United Pharma succeed in registering ‘Cilostan CR’ in foreign countries

Korea United Pharma(CEO Duk-young Kang) acquired product approval of ‘Cilostan CR,’ an incrementally modified drug, from the Philippine Food and Drug Administration(PFDA).  

Cilostan CR Tab, an incrementally modified antithrombotic drug launched in 2013 after its 5-year R&D program, is a product which innovatively improved administration compliance by modifying it from two a day to once a day ...